Please provide your email address to receive an email when new articles are posted on . For approval, generic fluticasone-salmeterol was required to be tested in only patients with asthma, not COPD.

HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela™ Inhub™ (fluticasone ...

wixela-product-image Mylan plans to make Wixela Inhub available in 3 strengths: 100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg. Wixela Inhub combines fluticasone propionate, a synthetic corticosteroid, ...

wixela-product-image Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan Mylan ...

Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline's GSK Advair Diskus - Wixela Inhub - following a few setbacks. Notably, this is the first ...

If Mylan’s aggressive pricing for its generic Advair product sounds familiar, that’s because it is. The knockoffs giant set the list price for Wixela Inhub, its copy of GlaxoSmithKline’s respiratory ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...

After the FDA shot down Mylan’s generic Advair for the second time in June, executives said they addressed the “minor deficiencies” and an approval should follow in mid-October. A week into November, ...

(Alliance News) - Consort Medical PLC on Thursday reported a "solid" annual performance, despite a 28% drop in profit. Drug and delivery device maker Consort reported pretax profit of GBP12.5 million ...

Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline’s GSK Advair Diskus — Wixela Inhub — following a few setbacks. Notably, this is the first ...